Blockchain Registration Transaction Record
TransCode's TTX-MC138 Poster to Debut at ESMO 2026
TransCode Therapeutics (NASDAQ: RNAZ) to present TTX-MC138 Phase 1a update at ESMO 2026. TTX-MC138 targets miR-10b in advanced cancers.
The upcoming ESMO presentation underscores the progress of TTX-MC138, a first-in-class RNA therapeutic targeting miR-10b, a key driver of metastasis. Positive Phase 1a data could validate TransCode's approach to treating metastatic cancers, potentially attracting investment and partnerships. For patients with advanced solid tumors, this represents a novel strategy that may address unmet needs. The news also highlights the role of communications platforms like NetworkNewsWire in disseminating critical developments to investors and the public.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x21b6395ddcc079fcfac2749cef23e8e5750a2c0e01508decb520ad0cbf387939 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | dash7ice-2d13335a795a00bb5391ec297db7f7ef |